Skip to main content
European Commission logo
français français
CORDIS - Résultats de la recherche de l’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary

Role and modulation of Zinc-finger antiviral protein and antiviral Regnase-1-like endonucleases

Description du projet

ZAPper les virus

Les cellules humaines ont développé divers mécanismes immunitaires destinés à inhiber la réplication des virus et à minimiser leur propagation. L’une de ces stratégies fait intervenir les protéines antivirales à doigts de zinc (ZAP pour Zinc-finger Antiviral Proteins) qui ciblent les ARN viraux par la reconnaissance des dinucléotides CpG. Financé par le programme Actions Marie Skłodowska-Curie, le projet EXPL ANTIVIR ENDONUC se propose d’exploiter le potentiel thérapeutique des ZAP en délimitant leur mécanisme d’action. Les chercheurs identifieront les cofacteurs ZAP responsables de l’activité ARNse contre les principaux pathogènes viraux respiratoires. Par ailleurs, le travail impliquera le criblage de divers composés pour leur potentiel à maintenir l’activité antivirale des ZAP.

Objectif

The human zinc finger antiviral protein (ZAP) is capable of inhibiting several major human pathogens, including Influenza A virus and SARS-CoV-2. ZAP specifically targets CpG dinucleotides in RNAs and might be one of the reasons why CpGs are strongly suppressed in the human genome. Successful viruses, such as HIV-1 and SARS-CoV-2, mimic human CpG suppression to partially evade the inhibitory effects of ZAP. However, especially under conditions of infection or inflammation when ZAP is expressed at high levels, it inhibits both CpG containing viral as well as cellular RNAs. Importantly, ZAP itself does not possess RNAse activity and is dependent on cofactors, such as KHNYN, to destroy viral RNAs. KHNYN is tightly regulated and inactivated by MALT-1, a cellular protease representing an important target in cancer immunotherapies. Although some progress has been made, the identity of ZAP cofactors as well as their mechanism(s) of action and therapeutic potential are poorly understood. This proposal aims to combine the expertise of the applicant (mechanistic studies of ZAP and RNA-targeting factors) and the host (respiratory viruses and antiviral drug development) to define how ZAP-dependent and independent antiviral endonucleases restrict major respiratory viral pathogens. In addition, it will be examined whether MALT-1 inhibitors that are currently in clinical trials against cancers allow to enhance and maintain the antiviral activity of ZAP and its cofactors thus offering prospects for the treatment of respiratory infections. Finally, potential side-effects on cellular RNAs and their impact on immune signalling, cell activation and infection outcome will be determined. The project will combine innovative CRISPR/Cas9 genome editing, in vitro virus infection platforms, novel functional assays and state-of-the-art deep sequencing technologies to significantly advance the knowledge on antiviral RNAses and to clarify whether they can be strengthened for antiviral therapy.

Champ scientifique (EuroSciVoc)

CORDIS classe les projets avec EuroSciVoc, une taxonomie multilingue des domaines scientifiques, grâce à un processus semi-automatique basé sur des techniques TLN.

Vous devez vous identifier ou vous inscrire pour utiliser cette fonction

Coordinateur

UNIVERSITAET ULM
Contribution nette de l'UE
€ 173 847,36
Adresse
HELMHOLTZSTRASSE 16
89081 Ulm
Allemagne

Voir sur la carte

Région
Baden-Württemberg Tübingen Ulm, Stadtkreis
Type d’activité
Higher or Secondary Education Establishments
Liens
Coût total
Aucune donnée